The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent

American Journal of Clinical Nutrition

Volumn 68, Issue 6 SUPPL., 1998, Pages

  Kennedy, Ann R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Division of Oncology   (United States)

Author keywords

Bowman Birk inhibitor; Carcinogenesis; Investigational New Drug; Protease inhibitor; Soybeans

Indexed keywords

ANTINEOPLASTIC AGENT; BOWMAN BIRK INHIBITOR; CHYMOTRYPSIN; NEW DRUG; PROTEINASE INHIBITOR; TRYPSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CONFERENCE PAPER; DIARRHEA; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; HAMSTER; MOUSE; NONHUMAN; RAT; SOYBEAN;

ANIMALIA; CANIS FAMILIARIS; CRICETINAE; GLYCINE MAX;

EID: 0031741056     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/68.6.1406S     Document Type: Conference Paper

References (75)

1. Kennedy AR. Overview: anticarcinogenic activity of protease inhibitors. In: Troll W, Kennedy AR, eds. Protease inhibitors as cancer chemopreventive agents. New York: Plenum Press, 1993:9-64.
2. Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-31.
3. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991;83:541-6.
4. Tominaga S. Cancer incidence in Japanese in Japan, Hawaii, and Western United States. NCI Monogr 1985;69:83-92.
5. Dunn JE. Cancer epidemiology in populations of the United States with emphasis on Hawaii and California and Japan. Cancer Res 1975;35:3240-5.
6. Haenszel W, Kurihara M. Studies of Japanese immigrants. I. Mortality from cancer and other diseases among Japanese in the US. J Natl Cancer Inst 1968;40:43-69.
7. Buell P. Changing incidence of breast cancer in Japanese-American women. J Natl Cancer Inst 1973;51:1479-83.
8. Sipos E. Dietary trends for vegetable proteins in foods. Inform 1990;1:753-7.
9. Kennedy AR. The evidence for soybean products as cancer preventive agents. J Nutr 1995;125:733S-43S.
10. St Clair W, Billings P, Carew J, Keller-McGandy C, Newberne P, Kennedy AR. Suppression of DMH-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res 1990;50:580-6.
11. Kennedy AR, Billings PC, Maki PA, Newberne P. Effects of various protease inhibitor preparations on oral carcinogenesis in hamsters induced by 7,12-dimethylbenz(a)anthracene. Nutr Cancer 1993; 19:191-200.
12. Kennedy AR, Szuhaj BF, Newberne PM, Billings PC. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 1993;19:281-302.
13. Yavelow J, Collins M, Birk Y, Troll W, Kennedy, AR. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress X-ray induced transformation in vitro. Proc Natl Acad Sci U S A 1985;82:5395-9.
14. Weed H, McGandy RB, Kennedy AR. Protection against dimethyl-hydrazine induced adenomatous tumors of the mouse colon by the dietary addition of an extract of soybeans containing the Bowman-Birk protease inhibitor. Carcinogenesis 1985;6:1239-41.
15. Billings PC, Newberne P, Kennedy AR. Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethyl-hydrazine. Carcinogenesis 1990;11:1083-6.
16. Messadi PV, Billings P, Shklar G, Kennedy AR. Inhibition of oral carcinogenesis by a protease inhibitor. J Natl Cancer Inst 1986;76:447-52.
17. Witschi H, Kennedy AR. Modulation of lung tumor development in mice with the soybean-derived Bowman-Birk protease inhibitor. Carcinogenesis 1989;10:2275-7.
18. von Hofe E, Newberne PM, Kennedy AR. Inhibition of N-nitrosomethylbenzylamine induced esophageal neoplasms by the Bowman-Birk protease inhibitor. Carcinogenesis 1991;12:2147-50.
19. Evans SM, Szuhaj BF, Van Winkle T, Michel K, Kennedy AR. Protection against metastasis of radiation induced thymic lymphosarcoma and weight loss in C57B1/6NCr1BR mice by an autoclave resistant factor present in soybeans. Radiat Res 1992;132:259-62.
20. Kennedy AR, Beazer-Barclay Y, Kinzler KW, Newberne PM. Suppression of carcinogenesis in the intestines of Min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res 1996;56:679-82.
21. Kennedy AR. In vitro studies of anticarcinogenic protease inhibitors. In: Troll W, Kennedy AR, eds. Protease inhibitors as cancer chemopreventive agents. New York: Plenum Press, 1993:65-91.
22. Chang JD, Kennedy AR. Suppression of c-myc by anticarcinogenic protease inhibitors. In: Troll W, Kennedy AR, eds. Protease inhibitors as cancer chemopreventive agents. New York: Plenum Press, 1993:265-80.
23. Kennedy AR. Prevention of carcinogenesis by protease inhibitors. Cancer Res 1994;54(suppl):1999S-2005S.
24. Kennedy AR, Billings PC. Anticarcinogenic actions of protease inhibitors. In: Cerutti PA, Nygaard OF, Simic MG, eds. Anticarcinogenesis and radiation protection. New York: Plenum Press, 1987:285-95.
25. Kennedy AR. Cancer prevention by protease inhibitors. Prev Med 1993;22:796-811.
26. Kennedy AR. The conditions for the modification of radiation transformation in vitro by a tumor promoter and protease inhibitors. Carcinogenesis 1985;6:1441-6.
27. Birk Y. Protease inhibitors of plant origin and role of protease inhibitors in human nutrition: overview. In: Troll W, Kennedy AR, eds. Protease inhibitors as cancer chemopreventive agents. New York: Plenum Press, 1993:97-106.
28. Kennedy AR. Letter to the editor. J Nutr 1996;126:584-5.
29. Birk Y. Proteinase inhibitors from plant sources. Methods Enzymol 1976;45:695-739.
30. Birk Y. The Bowman-Birk inhibitor. Int J Pept Protein Res 1985;25:113-31.
31. Kennedy AR. Chemopreventive agents: protease inhibitors. Pharmacol Ther 1998;78:167-209.
32. Yavelow J, Finlay TH, Kennedy AR, Troll W. Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res 1983;43:2454-9.
33. Rackis JJ, Wolf WJ, Baker EC. Protease inhibitors in plant foods: content and inactivation. In: Friedman M, ed. Nutritional and toxicological significance of enzyme inhibitors in foods. Adv Exp Med Biol 1986;199:299-347.
34. Liener IE. Protease inhibitors and lectins. Int Rev Biochem 1979;27:97-122.
35. Liener IE, Kakade ML. Protease inhibitors. In: Liener IE, ed. Toxic constituents of plant foodstuffs. Vol 2. New York: Academic Press, 1980:9-71.
36. Hwang DLR, Davis-Lin KT, Yang WK, Foard DE. Purification, partial characterization and immunological relationships of multiple low molecular weight proteinase inhibitors of soybean. Biochim Biophys Acta 1977;495:369-82.
37. Lee J-K, Park B-J, Yoo K-Y, Ahn Y-O. Dietary factors and stomach cancer: a case-control study in Korea. Int J Epidemiol 1995; 24:33-41.
38. Severson RK, Nomura AMY, Grove JS, Stemmermann GN. A prospective study of demographics, diet and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989;49:1857-60.
39. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Dietary effects of breast-cancer risk in Singapore. Lancet 1991; 337:1197-200.
40. Troll W, Frenkel K, Wiesner R. Protease inhibitors as anticarcinogens. J Natl Cancer Inst 1984;73:1245-50.
41. Goldstein BD, Witz G, Amoruso M, Troll W. Protease inhibitors antagonize the activation of polymorphonuclear leukocyte oxygen consumption. Biochem Biophys Res Commun 1979;88:854-60.
42. Witz G, Goldstein BD, Amoruso M, Stone DS, Troll W. Retinoid inhibition of superoxide anion radical production by human polymorphonuclear leukocytes stimulated with tumor promoters. Biochem Biophys Res Commun 1980;97:883-8.
43. 2 formation by activated human polymorphonuclear leukocytes. Carcinogenesis 1987; 8:1207-12.
44. St Clair WH, St Clair DK, Kennedy AR. Comparison of the Bowman-Birk protease inhibitor to WR1065 for protection against radiation-induced DNA, cellular and tissue damage. Cancer J 1991;4:278-82.
45. Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaya NF. Inhibition of cathepsin G and human granulocyte elastase by multiple forms of Bowman-Birk type soybean inhibitor. Biokhimiia 1993;58:1437-44 (in Russian).
46. Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 1997;344:133-8.
47. Billings PC, Carew JA, Keller-McGandy CE, Goldberg A, Kennedy AR. A serine protease activity in C3H/10T1/2 cells that is inhibited by anticarcinogenic protease inhibitors. Proc Natl Acad Sci U S A 1987;84:4801-5.
48. Billings PC, St Clair W, Owen AJ, Kennedy AR. Potential intracellular target proteins of the anticarcinogenic Bowman-Birk protease inhibitor identified by affinity chromatography. Cancer Res 1988;48:1798-802.
49. Billings PC, Morrow AR, Ryan CA, Kennedy AR. Inhibition of radiation-induced transformation of C3H/10T1/2 cells by carboxypeptidase inhibitor I and inhibitor II from potatoes. Carcinogenesis 1989;10:687-91.
50. Carew, JA, Kennedy AR. Identification of a proteolytic activity which responds to anticarcinogenic protease inhibitors in C3H10T1/2 cells. Cancer Lett 1990;49:153-63.
51. Oreffo VIC, Billings PC, Kennedy AR, Witschi H. Acute effects of the Bowman-Birk protease inhibitor in mice. Toxicology 1991; 69:165-76.
52. Billings PC, Habres JM, Kennedy AR. Inhibition of radiation-induced transformation of C3H10T1/2 cells by specific protease substrates. Carcinogenesis 1990;11:329-32.
53. Billings PC, Habres JM, Liao DC, Tuttle SW. A protease activity in human fibroblasts which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Res 1991;51:5539-43.
54. Billings PC, Habres JM. A growth regulated protease activity which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Proc Natl Acad Sci U S A 1992;89:3120-4.
55. Billings PC. Approaches to studying the target enzymes of anticarcinogenic protease inhibitors. In: Troll W, Kennedy AR, eds. Protease inhibitors as cancer chemopreventive agents. New York: Plenum Press, 1993:191-8.
56. Habres JM, Billings PC. Intestinal epithelial cells contain a high molecular weight protease subject to inhibition by anticarcinogenic protease inhibitors. Cancer Lett 1992;63:135-42.
57. Long S, Quigley J, Troll W, Kennedy AR. Protease inhibitor antipain suppresses TPA induction of plasminogen activator in transformable mouse embryo fibroblasts. Carcinogenesis 1981; 2:933-6.
58. Chang JD, Billings P, Kennedy AR. C-myc expression is reduced in antipain-treated proliferating C3H10T1/2 cells. Biochem Biophys Res Commun 1985;133:830-5.
59. Chang JD, Kennedy AR. Cell cycle progression of C3H10T1/2 and 3T3 cells in the absence of a transient increase in c-myc RNA levels. Carcinogenesis 1988;9:17-20.
60. Caggana M, Kennedy AR. C-fos mRNA levels are reduced in the presence of antipain and the Bowman-Birk inhibitor. Carcinogenesis 1989;10:2145-8.
61. Chang JD, Li J-H, Billings PC, Kennedy AR. Effects of protease inhibitors on c-myc expression in normal and transformed C3H10T1/2 cells. Mol Carcinog 1990;3:226-32.
62. St Clair WH, Billings PC, Kennedy AR. The effects of the Bowman-Birk protease inhibitor on c-myc expression and cell proliferation in the unirradiated and irradiated mouse colon. Cancer Lett 1990;52:145-52.
63. Li J-H, Billings PC, Kennedy AR. Induction of oncogene expression by sodium arsenite in C3H/10T1/2 cells; inhibition of c-myc expression by protease inhibitors. Cancer J 1992;5:354-8.
64. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK. Biomarkers as intermediate endpoints in chemoprevention trials. J Natl Cancer Inst 1990;82:555-60.
65. Kennedy AR, Little JB. Effects of protease inhibitors on radiation transformation in vitro. Cancer Res 1981;41:2103-8.
66. Manzone H, Billings PC, Cummings WN, et al. Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis. Cancer Epidemiol Biomarkers Prev 1995;4:521-7.
67. Persiani S, Yeung A, Shen WC, Kennedy AR. Polylysine conjugates of Bowman-Birk protease inhibitor as targeted anticarcinogenic agents. Carcinogenesis 1991;12:1149-52.
68. Ekrami H, Kennedy AR, Witschi H, Shen WC. Cationized Bowman-Birk protease inhibitor as a targeted cancer chemopreventive agent. J Drug Target 1993;1:41-9.
69. Ekrami H, Kennedy AR, Shen W-C. Disposition of positively-charged Bowman-Birk protease inhibitor conjugates in mice; influence of protein conjugate charge-density and size on lung targeting. J Pharm Sci 1995;84:456-61.
70. Ekrami HM, Kennedy AR, Shen W-C. Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides. FEBS Lett 1995;371:283-6.
71. Billings PC, Brandon DL, Habres JM. Internalization of the Bowman-Birk protease inhibitor by intestinal epithelial cells. Eur J Cancer 1991;27:903-8.
72. Billings PC, St Clair W, Maki PA, Kennedy AR. Distribution of the Bowman-Birk protease inhibitor in mice following oral administration. Cancer Lett 1992;62:191-7.
73. Madar Z, Gertler A, Birk Y. The fate of the Bowman-Birk trypsin inhibitor from soybeans in the digestive tract of chicks. Comp Biochem Physiol 1979;62:1057-61.
74. Brandon DL, Bates AH, Friedman M. Monoclonal antibody-based enzyme immunoassay of the Bowman-Birk protease inhibitor of soybeans. Agric Food Chem 1989;37:1192-6.
75. Wan XS, Koch CJ, Lord EM, et al. Monoclonal antibodies differentially reactive with native and reductively modified Bowman-Birk protease inhibitor. J Immunol Methods 1995;180:117-30.